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ABSTRACT: The molecular basis for high resistance to clinical
inhibitors of HIV-1 protease (PR) was examined for the variant
designated PRP51 that was selected for resistance to darunavir (DRV).
High resolution crystal structures of PRP51 with the active site D25N
mutation revealed a ligand-free form and an inhibitor-bound form
showing a unique binding site and orientation for DRV. This
inactivating mutation is known to increase the dimer dissociation
constant and decrease DRV aﬃnity of PR. The PRP51‑D25N dimers were
in the open conformation with widely separated ﬂaps, as reported for
other highly resistant variants. PRP51‑D25N dimer bound two DRV
molecules and showed larger separation of 8.7 Å between the closest
atoms of the two ﬂaps compared with 4.4 Å for the ligand-free
structure of this mutant. The ligand-free structure, however, lacked van
der Waals contacts between Ile50 and Pro81′ from the other subunit in the dimer, unlike the majority of PR structures. DRV is
bound inside the active site cavity; however, the inhibitor is oriented almost perpendicular to its typical position and exhibits only
2 direct hydrogen bond and two water-mediated interactions with atoms of PRP51‑D25N compared with 11 hydrogen bond
interactions seen for DRV bound in the typical position in wild-type enzyme. The atypical location of DRV may provide
opportunities for design of novel inhibitors targeting the open conformation of PR drug-resistant mutants.
HIV-1 protease (PR) has been a successful target in AIDS
therapy due to its critical role in viral maturation by hydrolyzing
the Gag and Gag-Pol precursor polyproteins into mature
structural and functional proteins.1,2 A series of clinical HIV-1
protease inhibitors (PIs) has improved the survival of AIDS
patients. One such inhibitor, darunavir (DRV), which was
designed to target drug resistance by introducing strong polar
interactions with the main chain atoms of the PR,3−5 has been
widely used for the treatment of drug-naiv̈e patients and those
infected with multidrug-resistant HIV-1.6 DRV eﬀectively
inhibits PR enzymatic activity with picomolar binding aﬃnity
assessed by isothermal titration calorimetry (ITC).7 However,
HIV evolves resistance to DRV by selecting a combination of
mutations.6
Highly DRV-resistant HIV-1 variants were selected in the
laboratory to elucidate the mechanism for resistance.8 A
mixture of 8 highly DRV-susceptible HIV-1 clinical isolates
(HIV-1MIX) containing 9−14 PI-resistant mutations was
propagated in the presence of DRV. The viral population at
passage 51 (HIV-1MIX
P51) replicated well at the concentration
of 5 μM DRV, and sequencing revealed 14 amino acid
substitutions in the PR gene (Figure 1).8 The viral strain HIV-
1MIX
P51 was highly resistant, with half maximal eﬀective
concentration (EC50) for inhibition of viral replication
increased to more than 1 μM for DRV and most other PIs,
and showed moderate resistance to saquinavir (SQV) (0.3 μM
EC50).
8
We have investigated the physical and biochemical properties
of several resistant variants, including the HIV-1MIX
P51 protease
(PRP51).
9 PRP51 and another highly resistant variant with 20
mutations (PR20) showed several extreme properties con-
tributing to resistance. The aﬃnity of DRV and SQV for PRP51
as measured by isothermal titration calorimetry (ITC) gave KL
values of 37 and 54 nM, respectively, or about 7400-fold and
135-fold weaker than the corresponding values for wild-type
PR. Autocatalytic cleavage (autoprocessing) of precursor Gag-
Pol polyprotein is essential to produce mature and fully active
PR.10 Autoprocessing of the precursor comprising the 56-
amino-acid transframe region (TFR) fused to PR (TFR-PR)
was inhibited the best by DRV and SQV as compared to other
clinical inhibitors, although in the low micromolar range.
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However, autoprocessing of the TFR-PRP51 precursor was
uninhibited by DRV and marginally inhibited by SQV, at 150
μM PI concentration.9 These properties of PRP51 are consistent
with the high antiviral resistance to DRV measured for virus
bearing this variant (>300-fold increased EC50) relative to wild-
type.8
We have reported recently the structural analysis of another
extremely resistant variant, PR20, which showed no inhibition
of precursor autoprocessing, and KL values for mature PR20
increased by more than 8000- and 2000-fold, respectively, for
DRV and SQV.9,11 Crystallographic analysis of PR20 showed
fewer interactions with inhibitors and widely separated ﬂaps in
the absence of inhibitors with no contact of the ﬂap with
residues from the other subunit, unlike interactions in the
corresponding structures of wild-type PR.12,13 An increased
separation of the ﬂaps in the dimer may be typical of many
resistant variants, as seen also for variant MDR76914 and in
solution studies using double electron−electron resonance
(DEER) spectroscopy.15
In order to further investigate the molecular mechanisms of
high-level resistance, we have determined the crystal structures
of PRP51 bearing the inactivating mutation D25N (PRP51‑D25N)
to abolish self-degradation (autoproteolysis) for sample
handing during crystallization. When the D25N mutation was
introduced into wild-type PR, the aﬃnity for DRV was
decreased by about 106-fold, while no substantial changes
were observed in the crystal structures.16 Two structures were
obtained for PRP51‑D25N: a DRV-bound structure (PRP51‑D25N/
DRV) and a ligand-free structure (PRP51‑D25N). Structural
analysis revealed an unusual binding site for DRV and the
widely separated ﬂaps that characterize the ligand-free
structures of many highly resistant variants.11,14,15
■ RESULTS AND DISCUSSION
Crystal Structures of Ligand-Free and DRV-Bound
PRP51‑D25N. Repeated attempts with active PRP51 did not yield
crystals, likely due to its enhanced autoproteolysis. Consistent
with this observation even storage of the protein in 12 mM HCl
prior to folding showed degradation products unlike the
optimized wild-type PR. The optimized wild-type PR bears the
mutations L33I and L63I shown to signiﬁcantly restrict
autoproteolysis of wild-type PR in addition to Q7K, which
exists in PRP51.
10,17 Also, as DRV interactions with PRD25N are
nearly identical to those in wild-type PR/DRV complex,16 we
resorted to using PRP51 with mutation D25N for our studies.
Crystals were grown of mutant PRP51‑D25N in the presence of
DRV, SQV, tipranavir (TPV), and amprenavir (APV) in order
to identify the structural changes associated with high level
resistance. Electron density for inhibitor DRV was observed
within the ligand binding cavity only in the structure of
PRP51‑D25N/DRV. No inhibitor was visible in the PRP51‑D25N
structure obtained from crystals grown in the presence of SQV,
APV, or TPV, consistent with the high level resistance of this
mutant. The two crystal structures designated PRP51‑D25N/DRV
and PRP51‑D25N were reﬁned with X-ray data at resolutions of
1.66 and 1.50 Å and R-factors of 18.9% and 15.9%, respectively.
The crystallographic statistics are listed in Supplementary Table
S1. PRP51‑D25N/DRV was reﬁned in space group P41212 with a
monomer of residues numbered 1−99 in the asymmetric unit,
while PRP51‑D25N was reﬁned in space group P41 and contained
Figure 1. PRP51 mutations. (A) Sites of the 14 drug resistant mutations mapped onto the PRP51 dimer (cyan cartoon representation). The mutations
located in the active site cavity are shown as red spheres, while the ﬂap mutations are shown as blue spheres, and the mutations distal from the active
site are indicated as green spheres. (B) Amino acid sequence of HIV-1 PR (upper line) and PRP51 (lower line). The amino acids are colored as in
panel A. Note that the wild-type PR sequence used for structural comparison includes mutations Q7K, L33I, and L63I to prevent autoproteolysis,
and both proteins include C67A and C95A to eliminate potential cysteine-thiol oxidation.
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one dimer of residues numbered 1−99 and 1′−99′ in the
asymmetric unit. Alternate conformations were reﬁned for 3
residues in PRP51‑D25N/DRV and 7 residues in PRP51‑D25N
structures. Residues 34−36 from each monomer of the two
structures showed similar alternate conformations with 0.5
relative occupancy. The crystallographic dimer of PRP51‑D25N/
DRV was generated for structural analysis.
PRP51-D25N/DRV Exhibits Unusual Binding Conforma-
tion of DRV. DRV placed at the typical binding site (Figure
2A)5,18 did not ﬁt the electron density visible in the ligand
binding cavity of PRP51‑D25N/DRV, and thus diﬀerent locations
were evaluated for the inhibitor. After manual adjustment, the
ﬁnal monomer structure was reﬁned with one full occupancy
molecule of DRV oriented approximately perpendicular to
DRV in the typical inhibitor-binding site of wild-type PR or
most mutants (Figure 2B), as indicated by the clear electron
density map (Figure 3A). The two molecules of DRV are
related by 180° rotation and interact with each other in the
binding cavity of the PRP51‑D25N dimer (Figure 3B). The polar
interactions between the two DRV molecules include a water-
mediated hydrogen bond connecting a sulfonyl oxygen and
hydroxyl group with the amino group on the aniline of the
other DRV and C−H···water interactions with the phenyl
group and the bis-THF of both DRVs. The bound DRV has
relatively few hydrogen bonds and many hydrophobic contacts
with the protein (Figure 3C and D).
This DRV molecule has a diﬀerent conformation and
interactions from those for the regular binding mode of
DRV, which has 11 direct hydrogen bond interactions and 4
water-mediated ones with PR in the wild-type PR/DRV
complex (PDB ID 2IEN) (Figure 4A and 4B).5 Many van
der Waals contacts were observed between PRP51‑D25N and DRV
with distances ranging from 3.8 to 4.2 Å. In the crystal structure
of PRP51‑D25N/DRV, DRV forms two direct hydrogen bonds
with the main chain amides of Gly49 and Gly50, and three
water molecules mediate hydrogen bond interactions with
Gly27, Asp30, and Gly27′ from the crystallographic dimer. van
der Waals interactions occurred between DRV and PRP51‑D25N
residues Asn25, Ala28, Ile47, Gly48, Gly49, Ile50, Gly52,
Phe53, Met54, Thr80, Pro81′, Ile82, and Val84. These
interacting residues include mutations of V32I, I54M, V82I,
and I84V from the selected P51 isolate and the D25N
mutation. It is probable that these mutations facilitate binding
of DRV to this atypical site. Introducing the single mutation
D25N in the wild-type enzyme, however, does not alter the
binding of DRV observed in the crystal structure.16 In addition,
DRV forms interactions with residues from other symmetry-
related molecules of PRP51‑D25N as shown in Figure 4B and
Supplementary Figure S1. The DRV molecule interacts with
Figure 2. DRV binds to diﬀerent sites in PR and PRP51‑D25N. (A) The structure of wild-type PR (gray color) with one conformation of DRV (red
sticks) (PDB ID 2IEN) bound perpendicular to the dimer interface. (B) A diﬀerent position and conformation was seen for the two molecules of
DRV (red sticks and pink sticks) bound symmetrically in the PRP51‑D25N dimer (green color). On the right side, the chemical structure of DRV is
indicated in approximately the same orientation for the two structures.
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Ile72 and Gln61 from two diﬀerent symmetry-related
monomers of PRP51‑D25N (Supplementary Figure S1). The
interactions include two direct hydrogen bonds between the
two oxygens of the bis-THF and the amino group on the side
chain of Gln61 and van der Waals contacts with Ile72 and
Gln61. The existence of DRV interactions with the symmetry-
related PRP51‑D25N raises the possibility that crystal lattice
contacts inﬂuence the atypical binding of the inhibitor.
The question of whether DRV might bind at this atypical site
in wild-type enzyme can be addressed by structural comparison.
The PRP51‑D25N/DRV monomer shares an almost identical wide
open conformation (RMSD of 0.33 Å on equivalent Cα atoms)
with the wild-type PR crystallized with Mg2+ coordinated at the
active site (PDB ID 2PC0).13 Superposition of the two
monomers reveals that three side chains of the wild-type
enzyme lie close to DRV in this atypical site (Figure 5). The
side chain of Ile54 in wild-type PR would hinder binding of the
second THF of the bis-THF group of DRV due to short
interatomic distances of 2.0−3.1 Å (Figure 5). Also, the side
chains of Val82 and Ile84 in wild-type PR extend closer to the
aniline group of DRV compared to the good hydrophobic
contacts formed by Ile82 and Val84 in PRP51‑D25N/DRV.
However, rotated conformers of the side chains of Ile54, Val82,
and Ile84 could allow the possible binding of DRV in the
atypical site.
The aﬃnity of DRV for binding in the typical location is
expected to be decreased drastically by the mutations. The
PRP51‑D25N variant showed 7,400-fold lower aﬃnity for DRV,
9
while introducing the single D25N mutation in the wild-type
enzyme produced about 106-fold decreased aﬃnity for DRV as
measured by ITC with no change in the stoichiometry of
binding.16 Therefore, the combination of D25N plus the 14
mutations in PRP51 is expected to compromise the aﬃnity to
low micromolar levels.16 Consequently, DRV may favor the
weaker atypical binding location observed in PRP51‑D25N.
It is not the ﬁrst time that DRV has been observed to bind at
an unusual site in HIV-1 protease variants. A second binding
site was observed in an ultrahigh resolution (0.84 Å) structure
of PRV32I/DRV in addition to the typical active site binding.
The second DRV bound in a groove on one ﬂap surface where
the residues Glu35′, Lys45′, Lys55′, Val56′, and Arg57′
participated in the major interactions.18 A similar DRV binding
site occurred in the crystal structures of PRM46L/DRV and
PR20/DRV.11,18 Also for SQV, a second molecule was found in
a location adjacent to the usual active site location in PR20/
SQV and PRV32I/I47V/V82I/SQV structures.
11,19 Another unique
binding mode was found for GB-18, speciﬁcally [3-cobalt
bis(1,2-dicarbollide)]-ion, which belongs to a novel class of
inorganic cobaltacarborane inhibitors, in the active site cavity of
the wild-type PR (PDB ID 1ZTZ).20 This binding mode
involves two molecules of GB-18 positioned asymmetrically
inside the pseudosymmetric active site cavity.20 These binding
pockets for GB-18 are formed by the residues Pro81, Ile84, and
Val82 and covered by the ﬂap residues Ile47, Gly48, and Ile54
forming a semiopen conformation of the PR dimer.20 The
cobaltacarborane complex was used to design novel inhibitors
with linkers between two metallocarboranes to permit ﬂexible
binding to drug-resistant mutants. A similar strategy can be
Figure 3. Unique binding site for DRV in PRP51‑D25N. (A) Fo − Fc omit map contoured at 2.0σ showing one molecule of DRV (yellow sticks) in the
crystal structure of the monomer of PRP51‑D25N/DRV. (B) Interaction between two DRV molecules in the PRP51‑D25N dimer (yellow sticks and cyan
sticks). Water molecules are shown as red spheres. The dotted lines represent the hydrogen bonds, and the dashed lines represent potential CH···O
interactions with the interatomic distances indicated in Å. (C,D) Interactions of DRV with PRP51‑D25N (green sticks). The interactions of DRV are
separated into panels C and D for clarity. The interacting residues are labeled, and mutations are indicated by underlining. The dotted lines show the
hydrogen bond interactions, and the double-sided arrows represent the van der Waals contacts. The number of van der Waals contacts is indicated.
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evaluated for inhibiting the open conformation dimer by
chemically linking two DRV molecules as seen in the
PRP51‑D25N/DRV complex.
Flaps of PRP51‑D25N/DRV and PRP51‑D25N Display Diﬀer-
ent Intersubunit Interactions. Both DRV-bound and ligand-
free PRP51‑D25N dimers have ﬂaps separated by a large distance
between their tips. The ﬂaps of PRP51‑D25N/DRV dimer had a
larger separation of 8.7 Å between the closest atoms, while the
ﬂaps were separated by 4.4 Å for PRP51‑D25N. Superposition of
the monomer of PRP51‑D25N/DRV with each subunit of the
ligand-free dimer gave the overall RMSD value of 0.97 and 0.41
Å on Cα atoms, respectively, with large diﬀerences in the
conformation of the two ﬂaps and 80′s loops (residues 79/79′
to 83/83′) (Figure 6A). One of the two ﬂaps (residues 47/47′
to 54/54′) of the PRP51‑D25N/DRV dimer is further away from
the catalytic site than seen for the equivalent ﬂap of PRP51‑D25N
as indicated by the distance of 5.6 Å between the equivalent Cα
atoms of Ile50 in these two structures, while the other ﬂap
conformation is more similar in the two structures with 1.5 Å
distance between the Cα atoms of Ile50′ residues (Figure 6B).
The two PRP51‑D25N dimer structures were compared with
open conformation structures of PR and PR20 as well as their
DRV-bound complexes. The open conformations of ligand-free
PR20 have two unusual features relative to other reported
dimer structures: widely separated ﬂaps and no intersubunit van
der Waals contacts between the ﬂap tip and residues from the
other subunit.11 Therefore, the conformations were assessed by
measuring the closest distance between atoms at the tip of the
two ﬂaps within one dimer structure and the closest
intersubunit contact of Ile50/50′ at the ﬂap tip with Pro81′/
81. The shortest interatomic distances between the ﬂap tips
were 4.0 Å in ligand-free PRP51‑D25N, compared to 3.0 Å in a
typical open conformation of wild-type PR (PDB ID 1HHP),
7.7 Å in another wild-type PR with Mg2+ coordinated at the
active site (PDB ID 2PC0), and 6.0 Å in ligand-free PR20
(PDB ID 3UF3).11−13
The various ﬂap conformations in wild-type PR (PDB ID
1HHP), ligand-free PRP51‑D25N, and ligand-free PR20 are
compared in Supplementary Figure S2A. For the DRV
complexes, the shortest interﬂap distance was 8.7 Å in
PRP51‑D25N/DRV compared with about 3.3 Å for typical closed
conformation dimers of PR/DRV (PDB ID 2IEN) and PR20/
DRV (PDB ID 3UCB) (Supplementary Figure S2B).5,11 Ile50/
50′ at the ﬂap tips has intersubunit van der Waals contacts of
about 4.0 Å with Pro81′/81 in PRP51‑D25N/DRV as observed for
closed conformation inhibitor-bound dimers. The majority of
dimers show intersubunit van der Waals contacts between
Figure 4. DRV has distinct hydrogen bond interactions with wild-type
PR (PDB ID 2IEN) (A) and PRP51‑D25N (B). DRV is represented in
gray sticks and yellow sticks in PR and PRP51‑D25N, respectively. The
dotted lines indicate hydrogen bond interactions. Water molecules are
represented by W. NH is the main chain amide group, and CO is
the main chain carbonyl group. Glu61 from a symmetry-related dimer
is shown in blue within parentheses.
Figure 5. Superposition of the monomers of PRP51‑D25N/DRV (green)
and wild-type PR (PDB ID 2PC0) (grey). The double-sided arrows
represent short interatomic contacts of 2.0−3.1 Å between DRV
(yellow) and side chains of Ile54, Val82, and Ile84 in wild-type PR.
Figure 6. Comparison of two structures of PRP51‑D25N. (A)
Superposition of the overall structures of PRP51‑D25N (pink) and
PRP51‑D25N/DRV (green). (B) The interactions of ﬂap residues 47−54
are shown in the blue box; the numbers beside the black arrows show
the distance in Å between corresponding Cα atoms of Ile50/50′ in the
two structures.
ACS Chemical Biology Articles
dx.doi.org/10.1021/cb4008875 | ACS Chem. Biol. 2014, 9, 1351−13581355
Ile50/50′ and Pro81′/81, except for the ligand-free PR20 where
these two side chains are separated by about 7 Å. In contrast,
this intersubunit contact was lost in ligand-free PRP51‑D25N since
the closest atoms of Ile50 and Pro81′ were separated by 8.5 Å.
The asymmetric ﬂap conformations of ligand-free PRP51‑D25N
resemble those of another open conformation dimer of PR20
(PDB ID 3UHL), which had van der Waals contact between
the ﬂap tips and asymmetric ﬂaps with 12.2 and 5.4 Å
intersubunit separation between Ile50/50′ and Pro81′/81
(Figure 7). Therefore, the large separation (∼7−12 Å) between
side chain atoms of Ile50 and Pro81′ from the other subunit is
conserved in the ligand-free dimers of the two highly resistant
mutants PR20 and PRP51‑D25N.
Multiple Mutations Contribute to the Structural
Changes in PRP51‑D25N. PRP51‑D25N bears 14 mutations
(L10I, I15V, K20R, L24I, V32I, L33F, M36I, M46L, I54M,
L63P, K70Q, V82I, I84V, and L89M) as well as D25N relative
to the standard wild-type PR sequence. Four mutations
associated with drug resistance, V32I, M46L, V82I, and I84V,
alter residues in the active site cavity where substrates and
inhibitors usually bind. Additionally, “second shell” mutations
L10I, L24I, L33F, and I54M alter residues that form direct
interactions with residues in the active site cavity. Our
crystallographic and biochemical analysis has demonstrated
the changes due to the individual single mutations of L24I,
V32I, M46L, I54M, and I84V, as reviewed in Weber and
Agniswamy.2 Several of the other substitutions in PRP51‑D25N are
shared by the highly resistant multiple mutant PR20, and their
coordinated eﬀects have been described previously.11
The mutations of residues V32I, V82I, and I84V in the active
site cavity are assumed to contribute to the poor aﬃnity of the
PRP51 mutant for inhibitors and the observed unusual binding
site for DRV in PRP51‑D25N (Figure 3). The side chains of these
residues form hydrophobic interactions with each other and
with Val47 in all structures. Mutants PRV32I and PRI47V have
altered interactions with inhibitors DRV and SQV;2,11 however,
V82I in the triple mutant PRV32I/I47V/V82I bearing the active site
residues of HIV-2 PR does not signiﬁcantly alter direct contacts
with inhibitor.19 Further comparison of inhibitor interactions is
limited since the crystal structures of the PRP51‑D25N mutant are
in the open conformation without inhibitor bound in the
standard active site location.
Mutations M46L and I54M alter residues in the ﬂaps and are
proposed to have small indirect eﬀects on inhibitor binding and
may alter the ﬂap dynamics.18,21,22 In PRP51‑D25N/DRV, the
I54M mutation introduced new van der Waals interactions with
DRV (Figures 3C and 5), while M46L had no contacts with the
ligand. The changes in interactions of mutated residue L24I are
similar in PRP51‑D25N and the single mutant PRL24I.
23 Ile24 gains
two good van der Waals contacts with Leu90 and loses or
elongates contacts (4.7 and 4.2 Å in the two subunits compared
to 3.8 Å distance in wild-type PR) with Phe99′ from the other
subunit. Unlike the mutated side chain of L10F in PR20/DRV,
in which a new hydrophobic contact was formed between the
side chains of Phe10 and mutated Ile82,11 mutated residue L10I
in PRP51‑D25N yields no new interactions with nearby residues.
Mutation L33F introduces the large bulky Phe side chain,
which maintains hydrophobic contacts of the wild-type enzyme,
including contacts with mutated residues I15V, M36I
substituting shorter side chains as reported for L33F in
PR20.11 Also, the ﬂap hinge region comprising residues 34 to
43 shares a very similar conformation in PRP51‑D25N and in the
ligand free conformation of PR20, which is likely due to the
presence of mutations M36I and I33F in both highly drug-
resistant variants. The mutations in the ﬂap hinge and ﬂaps are
likely to contribute to the extended ﬂap conformations
observed in PRP51‑D25N and in inhibitor-free PR20 structures.
Mutation L89M has not been analyzed previously in
structures. The side chain of Leu89 in wild-type PR forms
hydrophobic contacts with the side chains of Ile64, Ile66, Ala71,
Gly73, Ile85, and Asn88, as well as van der Waals and C−H···O
interactions with the side chain of Thr31 (Figure 8). The
mutated Met89 forms very similar contacts in PRP51‑D25N,
except for an additional van der Waals contact with the side
chain of Val75. Mutation K20R alters a residue near the protein
surface showing varied interactions with other surface side
chains. Mutations L63P and K70Q also alter surface side chains
that form a hydrophobic contact in the wild-type PR, which is
eliminated in the mutant PRP51‑D25N.
Conclusions. Two crystal structures were analyzed for the
PRP51‑D25N variant that was selected for high levels of resistance
to DRV. These structures conﬁrm the increased separation of
the two ﬂaps in the dimer and/or loss of intersubunit contacts
between the ﬂap tip and Pro81 in comparison to the open
conformations seen for the ligand-free wild-type PR, as
previously described for the MDR76914 and PR2011 highly
resistant variants. Other highly resistant PR mutants have
shown greater ﬂap mobility in studies employing various
techniques11,14,15,24 and decreased interactions with inhibitors
or substrate analogues in crystal structures.11,25,26 In PRP51‑D25N,
however, DRV showed a unique mode of binding within the
open conformation ﬂaps and lying almost perpendicular to the
typical active site position. Importantly, this new binding site
for DRV may hint at designs for novel types of antiviral
Figure 7. Comparison of dimers of PRP51‑D25N and PR20/p2-NCopen
(PDB ID 3UF3). (A) Superposition of the overall structures of
PRP51‑D25N (pink) and PR20/p2-NCopen (PDB ID 3UHL, blue). (B)
The ﬂap residues 47−53 and Pro81 of PRP51‑D25N and PR20/p2-
NCopen are shown below. The numbers beside the black arrows show
the distance in Å between Ile50 and Pro81′.
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inhibitors that capture the open, inactive conformation of the
protease.
■ METHODS
Construction, Expression, and Puriﬁcation. The HIV-1 PR
from Group M (Genbank HIVHXB2CG) is designated as PR. The
PRP51 construct contains 14 mutations (L10I, I15V, K20R, L24I, V32I,
L33F, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, and L89M) plus
three other mutations Q7K to minimize autoproteolysis and C67A and
C95A to prevent cysteine-induced aggregation.9,10,27 The mutant
DNA was constructed by oligonucleotide synthesis and cloned into the
pET11a vector between Nde1 and BamH1 restriction sites. To
eliminate autoproteolysis, the inactivating mutation of D25N was
introduced using the QuikChange II Site-Directed Mutagenesis Kit
and conﬁrmed by DNA sequencing. The protein was expressed in
Escherichia coli BL21(DE3), puriﬁed and folded using the protocol
described previously.28,29
Crystallization and Data Collection. Crystals of PRP51
(including the D25N mutation) complexed with clinical inhibitors
DRV and SQV were obtained by the hanging-drop vapor-diﬀusion
method at RT using 24 well VDX plates (Hampton Research, Aliso
Viejo, CA, USA). PRP51 with a monomer concentration of 1.29 mg
mL−1 was mixed with the inhibitors at 5−10-fold molar excess.
Screening Kit I solutions (Hampton Research, Aliso Viejo, CA, USA)
gave good crystals of PRP51 complexed with DRV (0.1 M HEPES
sodium pH 7.5, 0.8 M potassium sodium tartrate tetrahydrate) and
crystals of PRP51‑D25N grown in the presence of SQV (0.1 M imidazole
pH 6.5, 1.0 M sodium acetate trihydrate). The crystals were frozen in
liquid nitrogen using 25% (v/v) glycerol as a cryoprotectant. X-ray
diﬀraction data were collected at 100 K by remote access on the
beamline BM-22 of the Southeast Regional Collaborative Access Team
(SER-CAT), the Advanced Photon Source, Argonne National
Laboratory, Chicago.
Data Processing and Structure Determination. The X-ray data
were indexed, integrated, and scaled with HKL2000.30 The structures
were solved by molecular replacement with MOLREP in the CPP4i
suite of programs31 using the PR20 complex with Yb+ (PDB ID 3UF3)
as the starting model.11 The structures were reﬁned by REFMAC 5.2
in the CCP4 program suite 6.1.1332 and reﬁtted using COOT 0.6.1.33
Alternate conformations were modeled for PR residues, inhibitors, and
solvent molecules based on the observed electron density maps.
Anisotropic B factor reﬁnement was applied for the higher resolution
structure, and TLS restrained reﬁnement was used for the lower
resolution structure. Structural ﬁgures were prepared with PyMol.34
Protein Data Bank Accession Codes. The structure coordinates
and factors have been deposited in the Protein Data Bank with access
codes 4NPT for PRP51‑D25N-DRV and 4NPU for PRP51‑D25N.
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